Why Eikon Therapeutics, Inc.’s (EIKN) Stock Is Down 5.20%
As of Friday, July 31, Eikon Therapeutics, Inc.’s EIKN share price has dipped by 5.20%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
Commentary & Analysis
Why Eikon Therapeutics, Inc.’s (EIKN) Stock Is Down 6.38%
As of Tuesday, July 28, Eikon Therapeutics, Inc.’s EIKN share price has dipped by 6.38%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Eikon Therapeutics, Inc.’s (EIKN) Stock Is Up 7.87%
As of Monday, July 27, Eikon Therapeutics, Inc.’s EIKN share price has surged by 7.87%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Eikon Therapeutics, Inc.’s (EIKN) Stock Is Down 7.75%
As of Friday, July 10, Eikon Therapeutics, Inc.’s EIKN share price has dipped by 7.75%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Eikon Therapeutics, Inc.’s (EIKN) Stock Is Up 6.67%
As of Thursday, July 09, Eikon Therapeutics, Inc.’s EIKN share price has surged by 6.67%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | EIKN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $498.6 | $252.6 | 37% |
|
| Shares Out (Mil) | 33.7 | 52.3 | 39% |
|
| Institutional Ownership | 86.6% | 92.1% | 54% |
|
| Float (Mil) | 29.8 | 40.2 | 36% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 244 | 455 | 48% |
|
| Price Change (52-week) |
na | 52.9% | na |
|
| Growth | EIKN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (9.9%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | EIKN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($339) | ($43) | 4% |
|
| EPS (TTM) | ($32.189) | ($1.600) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($224) | ($31) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $123 | $5 | 80% |
|
| Long-Term Debt (Q1) (Mil) | $245 | $5 | 52% |
|
| Enterprise Value (Q1) (Mil) | $243 | $180 | 28% |
|
| Valuation | EIKN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.91 | 2.56 | 20% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | EIKN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (79.7%) | (49.8%) | 7% |
|
| ROE | (123.1%) | (55.5%) | 8% |
|
| Liabilities to Assets | 35.3% | 30.3% | 26% |
|
| F-Score | 1 | 3 | na |
|
Eikon Therapeutics, Inc. did not pass any screens on 7/31/2026.
